ZLSCF (ZYUS Life Sciences) 1-Year Share Buyback Ratio: -8.30% (As of Mar. 2026 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is ZYUS Life Sciences 1-Year Share Buyback Ratio?

ZYUS Life Sciences ZLSCF 1-Year Share Buyback Ratio is -8.30 as of Mar. 2026. The stock has 7 warning signs investors should review. Among 495 Drug Manufacturers companies, ZYUS Life Sciences ranks worse than 69.09% on this metric.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. ZYUS Life Sciences's current 1-Year Share Buyback Ratio was -8.30%.

ZLSCF's 1-Year Share Buyback Ratio is ranked worse than
69.09% of 495 companies
in the Drug Manufacturers industry
Industry Median: -2.1 vs ZLSCF: -8.30

ZYUS Life Sciences  (OTCPK:ZLSCF) 1-Year Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

ZYUS Life Sciences 1-Year Share Buyback Ratio Related Terms

ZLSCF vs RMTI, BTAI, MRMD: 1-Year Share Buyback Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, ZYUS Life Sciences's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ZYUS Life Sciences 1-Year Share Buyback Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ZYUS Life Sciences's 1-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where ZYUS Life Sciences's 1-Year Share Buyback Ratio falls into.


ZYUS Life Sciences 1-Year Share Buyback Ratio Calculation

ZYUS Life Sciences's 1-Year Share Buyback Ratio for the quarter that ended in Mar. 2026 is calculated as

1-Year Share Buyback Ratio=(Shares Outstanding (EOP) (Mar. 2025 ) - Shares Outstanding (EOP) (Mar. 2026 )) / Shares Outstanding (EOP) (Mar. 2025 )
=(74.358 - 80.523) / 74.358
=-8.3%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a 1-Year Share Buyback Ratio of -8.30 mean?
ZYUS Life Sciences (ZLSCF) has a 1-Year Share Buyback Ratio of -8.30 as of Mar. 2026. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for ZYUS Life Sciences and its competitors. According to the industry distribution chart, ZYUS Life Sciences ranks #342 out of 495 companies in the Drug Manufacturers industry, placing it in the top 69.1%.
Is ZYUS Life Sciences' 1-Year Share Buyback Ratio too high?
ZYUS Life Sciences' current 1-Year Share Buyback Ratio is -8.30. Based on the distribution chart, ZYUS Life Sciences ranks #342 out of 495 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does ZYUS Life Sciences' 1-Year Share Buyback Ratio compare to RMTI and BTAI?
According to the Drug Manufacturers industry distribution chart, ZYUS Life Sciences ranks #342 out of 495 companies for 1-Year Share Buyback Ratio. This places ZYUS Life Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Share Buyback Ratio for a Drug Manufacturers company?
A good 1-Year Share Buyback Ratio depends on the Drug Manufacturers industry context. However, 1-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Share Buyback Ratio mean?
A high 1-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for ZYUS Life Sciences and its competitors. ZYUS Life Sciences's current 1-Year Share Buyback Ratio is -8.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ZYUS Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, ZYUS Life Sciences (ZLSCF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.61, compared to a current price of $0.01 — trading 98.2% below its estimated fair value. The current 1-Year Share Buyback Ratio is -8.30. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Share Buyback Ratio calculated?
1-Year Share Buyback Ratio is calculated from a company's financial statements. For ZYUS Life Sciences (ZLSCF), the current 1-Year Share Buyback Ratio is -8.30 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ZYUS Life Sciences Business Description

Other Exchanges ZYUS:Canada
Address 407 Downey Road, Unit 204, Saskatoon, SK, CAN, S7N 4L8
ZYUS Life Sciences Corp is primarily engaged in the world-wide development and commercialization of cannabinoid-based therapeutics and product candidates. It is a licensed producer and distributor of medical cannabis for both medical and adult recreational access in Canada. The company has one reportable segment: Bio-pharmaceutical Products (including medical cannabis derivatives). Geographically, it operates in Canada; United States; Australia; and European Union.